Cara Therapeutics

Cara Therapeutics

A company developing treatments for pain, inflammation and pruritus

All edits

Edits on 17 April, 2020
Golden AI
Golden AI edited on 17 April, 2020 5:54 am
Edits made to:
Infobox (+1 properties)
Edits on 14 March, 2020
Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 14 March, 2020 2:39 pm
Edits made to:
Article (+4/-4 characters)

Article

CaraCara is developing a proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain and pruritus (itch) without inducing many of the side effects typically associated with other pain and itch therapeutics.

Edits on 3 December, 2019
Golden AI
Golden AI edited on 3 December, 2019 3:41 pm
Edits made to:
Infobox (+1 properties)

Infobox

Investors
Edits on 19 November, 2019
Golden AI
Golden AI edited on 19 November, 2019 3:36 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 11 November, 2019
Golden AI
Golden AI edited on 11 November, 2019 1:49 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 29 October, 2019
Golden AI
Golden AI edited on 29 October, 2019 6:58 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 12 June, 2019
Golden AI
Golden AI edited on 12 June, 2019 9:51 pm
Edits made to:
Infobox (+1 properties)
Golden AI
Golden AI edited on 12 June, 2019 9:49 pm
Edits made to:
Infobox (+1 properties)
Golden AI
Golden AI edited on 12 June, 2019 9:44 pm
Edits made to:
Infobox (+1 properties)
Edits on 29 March, 2019
Dawson Sewell
Dawson Sewell edited on 29 March, 2019 4:19 pm
Edits made to:
Infobox (+3 properties)
Article (+904/-795 characters)
Categories (+1/-2 topics)
Related Topics (+1 topics)

Article

Cara Therapeutics is a publicly held biotechnologybiotechnology company based in Stamford, Connecticut that was founded in 2004 by Derek Chalmers, Frederique Menzaghi, and Michael E. Lewis. It is focused on developing therapeutics to treat pain, inflammation, and pruritus. This is done by selectively targeting peripheral kappa opiod receptors (KORs).

Cara is developing a proprietrary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain and pruritus (itch) without inducing many of the side effects typically associated with other pain and itch therapeutics.

...

Cara is developing a proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain and pruritus (itch) without inducing many of the side effects typically associated with other pain and itch therapeutics.

Products

CR845

...

Korsuva

The product, Korsuva, has been formulated both as an IV and oral formulation and is being studied for acute pain, chronic pain, and uremic pruritus (itch). An injectible version of Korsuva is ready for commercialization, while the oral version for Puritus CKD and Pruritus CLD are in Phase 3 and Phase 2 of clinical studies respectively. An IV Difelikefalin version of CR845 is ready for commercialization for use in post-op settings and another oral difelikefalinDifelikefalin version has completed Phase 3 clinical studies for chronic pain and is progressing to commercialization.

CR701

Cara also has a product in preclinical development. CR701 selectively modulates CB receptors without targeting CNS cannabinoid receptors. It is intended to be developed as a therapeutic approach for neuropathic pain. The product has been evaluated in rodent models of neuropathic pain that produces both hyperalgesia (sensitization of nerve endings to painful stimuli) and allodynia (painful perception of innocuous stimuli) comparable to human conditions.

...

Cara also has a product in preclinical development. CR701 selectively modulates CB receptors without targeting CNS cannabiniod receptors. It is intended to be developed as a therapeutic approach for neuropathic pain. The product has been evaludated in rodent models of neuropathic pain that produces both hyperalgesia (sensitization of nerve endings to painful stimuli) and allodynia (painful perception of innocuous stimuli) comparable to human conditions.

Infobox

Date incorporated
July 2, 2004

Categories

Related Topics

Edits on 28 March, 2019
Carla Faraguna
Carla Faraguna edited on 28 March, 2019 8:28 pm
Edits made to:
Infobox (+1 properties)

Infobox

Industry
Edits on 21 January, 2019
Golden AI"Changed markets to industries"
Golden AI edited on 21 January, 2019 10:10 pm
Edits made to:
Infobox (+2/-2 properties)
Edits on 15 January, 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 15 January, 2019 2:13 pm
Edits made to:
Article (+12/-12 characters)

Article

The product, Korsuva, has been formulated both as an IV and oral formulation and is being studied for acute pain, chronic painchronic pain, and uremic pruritus (itch). An injectible version of Korsuva is ready for commercialization, while the oral version for Puritus CKD and Pruritus CLD are in Phase 3 and Phase 2 of clinical studies respectively. An IV Difelikefalin version of CR845 is ready for commercialization for use in post-op settings and another oral difelikefalin version has completed Phase 3 clinical studies for chronic pain and is progressing to commercialization.

Edits on 10 January, 2019
Golden AI
Golden AI edited on 10 January, 2019 9:45 am
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 9 January, 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 9 January, 2019 7:16 pm
Edits made to:
Article (+21/-21 characters)

Article

Cara Therapeutics is a publicly held biotechnology company based in Stamford, ConnecticutStamford, Connecticut. It is focused on developing therapeutics to treat pain, inflammation, and pruritus. This is done by selectively targeting peripheral kappa opiod receptors (KORs).

Sameeha Sulaiman
Sameeha Sulaiman edited on 9 January, 2019 12:05 pm
Edits made to:
Infobox (+1/-1 properties)
Article (+2077 characters)
People (+7 rows) (+14 cells) (+279 characters)
Further reading (+2 rows) (+8 cells) (+430 characters)

Article

Cara Therapeutics is a publicly held biotechnology company based in Stamford, Connecticut. It is focused on developing therapeutics to treat pain, inflammation, and pruritus. This is done by selectively targeting peripheral kappa opiod receptors (KORs).

Cara is developing a proprietrary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain and pruritus (itch) without inducing many of the side effects typically associated with other pain and itch therapeutics.

Cara's lead product candidate, CR845, is a potent peripheral kappa opiod receptor agonist with high selectivity over other opiod receptors in the body. It exhibits potent analgesic, anti-inflammatory, and anti-pruritic (anti-itch) properties in both human and animals. In addition, CR845 is intrinsically poor at penetrating the blood-brain barrier and therefore, has shown little side effects such as nausea/vomitting, sedation, respiratory depression, abuse, addiction, or euphoria.

The product, Korsuva, has been formulated both as an IV and oral formulation and is being studied for acute pain, chronic pain, and uremic pruritus (itch). An injectible version of Korsuva is ready for commercialization, while the oral version for Puritus CKD and Pruritus CLD are in Phase 3 and Phase 2 of clinical studies respectively. An IV Difelikefalin version of CR845 is ready for commercialization for use in post-op settings and another oral difelikefalin version has completed Phase 3 clinical studies for chronic pain and is progressing to commercialization.

...

Cara also has a product in preclinical development. CR701 selectively modulates CB receptors without targeting CNS cannabiniod receptors. It is intended to be developed as a therapeutic approach for neuropathic pain. The product has been evaludated in rodent models of neuropathic pain that produces both hyperalgesia (sensitization of nerve endings to painful stimuli) and allodynia (painful perception of innocuous stimuli) comparable to human conditions.

People

Name
Role
Related Golden topics

Derek Chalmers

CEO, President, & Director

Eric Vandal

VP of Commercial Operations

Frederique Menzaghi

Senior VP of Research and Development

Jo Goncalves

Chief Medical Officer

Mani Mohindru

CFO & Chief Strategy Officer

Michael E. Lewis

Chief Scientific Advisor

Scott Terrillion

General Counsel

Further reading

Title
Author
Link
Type

Jefferies Projects $573M Peak Sales For Cara Therapeutics' Lead Candidate (NASDAQ:CARA)

Shanthi Rexaline

Web

Infobox

Edits on 12 December, 2018
Golden AI"Import data"
Golden AI edited on 12 December, 2018 1:11 am
Edits made to:
Infobox (+4 properties)
People (+8 rows) (+16 cells) (+175 characters)

People

Name
Role
Related Golden topics

Angelo Calvello

Investor

Daniel M. Houde

Employee

Daniel Sarraf

Investor

Joe Stauffer

Employee

Jonathan Morgan

Investor

Nathan Low

Investor

Randy Anthony

Investor

William O. Pate II

Investor

Infobox

Edits on 18 September, 2018
Golden AI"Import data from spreadsheet"
Golden AI edited on 18 September, 2018 7:58 pm
Edits made to:
Categories (+1 topics)

Categories

Edits on 19 July, 2018
Golden AI"Update locations in infobox"
Golden AI edited on 19 July, 2018 8:52 pm

Infobox

Edits on 16 July, 2018
Golden AI"Update markets in infobox"
Golden AI edited on 16 July, 2018 11:38 pm

Infobox

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.